^
Association details:
| Biomarker: | MYC rearrangement + BCL6 rearrangement |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | (vincristine + Rituxan (rituximab) + doxorubicin hydrochloride + prednisone + cyclophosphamide + etoposide IV) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2131 Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number
Published date:
11/04/2020
Excerpt:
These results confirm the favourable outcome of patients with MYC and BCL-2 and/or BCL-6 rearrangements or gene ICN with R-DA-EPOCH therapy.
